A 6 Week Double-Blind, Placebo-Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of AZD1236as an Oral Tablet in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2017
At a glance
- Drugs AZD 1236 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Acronyms CERA
- 15 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jul 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 06 Feb 2009 New trial record